Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 30, 2019

SELL
$18.93 - $24.75 $5,679 - $7,425
-300 Closed
0 $0
Q3 2018

Oct 22, 2018

BUY
$15.87 - $22.4 $4,761 - $6,720
300 New
300 $5,000
Q2 2018

Jul 13, 2018

SELL
$18.56 - $22.45 $5,568 - $6,735
-300 Closed
0 $0
Q2 2017

Aug 11, 2017

BUY
N/A
300
300 $7,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Wespac Advisors So Cal, LLC Portfolio

Follow Wespac Advisors So Cal, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wespac Advisors So Cal, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wespac Advisors So Cal, LLC with notifications on news.